Your browser doesn't support javascript.
loading
Fluoroquinolone-resistant Streptococcus agalactiae isolates from Argentina.
Faccone, D; Guerriero, L; Méndez, E; Errecalde, L; Cano, H; Yoyas, N; Togneri, A; Romanowski, V; Galas, M; Whonet, Red; Corso, A.
Afiliación
  • Faccone D; Senrvicio Antimicrobianos, INEI-ANLIS Dr. Carlos G. Malbran, Ciudad Autónoma de Buenos Aires, Argentina.
Rev Argent Microbiol ; 42(3): 203-7, 2010.
Article en En | MEDLINE | ID: mdl-21180391
ABSTRACT
Fluoroquinolone resistance is a growing problem that has only recently emerged in S. agalactiae. Between 2005-2007, WHONET--Argentina network evaluated levofloxacin susceptibility in 1128 clinical S. agalactiae isolates, 10 (0.9%) of which proved to be resistant. Nine of them had come from 5 hospitals (in Buenos Aires City and 4 Argentinean provinces) and recovered from urine (n=7) and vaginal screening cultures (n=2). Three strains were also resistant to macrolides, lincosamides and B streptogramins due to the ermA gene. All nine fluoroquinolone-resistant isolates bore the same two mutations, Ser79Phe in ParC and Ser81Leu in GyrA proteins. Genetic relationships were analyzed by Apal-PFGE and two clones were determined, A (n=6) and B (n=3). To our knowledge, these are the first fluoroquinolone-resistant S. agalactiae isolates detected in Latin America.
Asunto(s)
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Streptococcus agalactiae / Fluoroquinolonas / Antibacterianos Tipo de estudio: Clinical_trials Límite: Humans País/Región como asunto: America do sul / Argentina Idioma: En Revista: Rev Argent Microbiol Año: 2010 Tipo del documento: Article País de afiliación: Argentina
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Streptococcus agalactiae / Fluoroquinolonas / Antibacterianos Tipo de estudio: Clinical_trials Límite: Humans País/Región como asunto: America do sul / Argentina Idioma: En Revista: Rev Argent Microbiol Año: 2010 Tipo del documento: Article País de afiliación: Argentina